By blocking this signal through Sirpα binding, the surface of the tumor cells is coated with the drug, allowing the CD40L side to bind to CD40 on APCs, which will lead to enhanced antigen presentation to CD8+ and CD4+ T lymphocytes and tumor cell phagocytosis. This evidence concerns the gene SIRPA and neoplasm.